Beijing Strong Biotechnologies, Inc. (300406.SZ)
CNY 14.0
(0.65%)
CNY 14.0
(0.65%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 702.74 Million CNY | 9.56% |
| 2022 | 594.22 Million CNY | 3.29% |
| 2021 | 575.29 Million CNY | 76.33% |
| 2020 | 326.25 Million CNY | 69.47% |
| 2019 | 192.52 Million CNY | 3.92% |
| 2018 | 185.25 Million CNY | 4.36% |
| 2017 | 177.51 Million CNY | 16.29% |
| 2016 | 152.65 Million CNY | 21.27% |
| 2015 | 125.87 Million CNY | 1.75% |
| 2014 | 123.71 Million CNY | 30.9% |
| 2013 | 94.5 Million CNY | 20.3% |
| 2012 | 78.55 Million CNY | 58.85% |
| 2011 | 49.45 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 148.62 Million CNY | -18.47% |
| 2024 Q3 | 174.94 Million CNY | 23.07% |
| 2024 Q2 | 151.43 Million CNY | 1.89% |
| 2023 Q3 | 162.05 Million CNY | -2.95% |
| 2023 Q4 | 182.29 Million CNY | 12.49% |
| 2023 FY | 651.06 Million CNY | 9.56% |
| 2023 Q1 | 139.71 Million CNY | 5.37% |
| 2023 Q2 | 166.99 Million CNY | 19.52% |
| 2022 FY | 594.22 Million CNY | 3.29% |
| 2022 Q4 | 132.59 Million CNY | -25.95% |
| 2022 Q3 | 179.05 Million CNY | 21.96% |
| 2022 Q2 | 146.81 Million CNY | 8.15% |
| 2022 Q1 | 135.75 Million CNY | -4.68% |
| 2021 Q1 | 106.07 Million CNY | -20.54% |
| 2021 Q2 | 150.47 Million CNY | 41.87% |
| 2021 FY | 575.29 Million CNY | 76.33% |
| 2021 Q3 | 176.33 Million CNY | 17.18% |
| 2021 Q4 | 142.41 Million CNY | -19.24% |
| 2020 Q4 | 133.49 Million CNY | 46.68% |
| 2020 Q3 | 91.01 Million CNY | 69.54% |
| 2020 Q2 | 53.68 Million CNY | 11.68% |
| 2020 FY | 326.25 Million CNY | 69.47% |
| 2020 Q1 | 48.06 Million CNY | -16.02% |
| 2019 Q2 | 41.16 Million CNY | -16.17% |
| 2019 FY | 192.52 Million CNY | 3.92% |
| 2019 Q4 | 57.23 Million CNY | 27.16% |
| 2019 Q3 | 45.01 Million CNY | 9.34% |
| 2019 Q1 | 49.1 Million CNY | -3.95% |
| 2018 Q2 | 49.53 Million CNY | 8.73% |
| 2018 Q3 | 39.03 Million CNY | -21.19% |
| 2018 FY | 185.25 Million CNY | 4.36% |
| 2018 Q1 | 45.55 Million CNY | -3.38% |
| 2018 Q4 | 51.12 Million CNY | 30.96% |
| 2017 Q3 | 45.44 Million CNY | 5.05% |
| 2017 Q4 | 47.15 Million CNY | 3.76% |
| 2017 FY | 177.51 Million CNY | 16.29% |
| 2017 Q1 | 41.65 Million CNY | -3.85% |
| 2017 Q2 | 43.25 Million CNY | 3.84% |
| 2016 Q1 | 30.95 Million CNY | 1.04% |
| 2016 Q2 | 41.36 Million CNY | 33.62% |
| 2016 FY | 152.65 Million CNY | 21.27% |
| 2016 Q4 | 43.32 Million CNY | 17.11% |
| 2016 Q3 | 36.99 Million CNY | -10.56% |
| 2015 Q2 | 34.21 Million CNY | 22.4% |
| 2015 Q1 | 27.95 Million CNY | -28.22% |
| 2015 Q4 | 30.63 Million CNY | -7.34% |
| 2015 FY | 125.87 Million CNY | 1.75% |
| 2015 Q3 | 33.06 Million CNY | -3.37% |
| 2014 Q4 | 38.94 Million CNY | 31.22% |
| 2014 Q2 | 28.33 Million CNY | 5.89% |
| 2014 Q1 | 26.75 Million CNY | -2.23% |
| 2014 FY | 123.71 Million CNY | 30.9% |
| 2014 Q3 | 29.67 Million CNY | 4.75% |
| 2013 FY | 94.5 Million CNY | 20.3% |
| 2013 Q4 | 27.36 Million CNY | 13.34% |
| 2013 Q3 | 24.14 Million CNY | 0.0% |
| 2012 FY | 78.55 Million CNY | 58.85% |
| 2011 FY | 49.45 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 3.35 Billion CNY | 79.04% |
| Hangzhou Tigermed Consulting Co., Ltd. | 358.41 Million CNY | -96.069% |
| Dirui Industrial Co.,Ltd. | 387.16 Million CNY | -81.51% |
| Medicalsystem Biotechnology Co., Ltd. | 562.06 Million CNY | -25.029% |
| Maccura Biotechnology Co.Ltd | 1.18 Billion CNY | 40.467% |
| Guangzhou Wondfo Biotech Co.,Ltd | 1.17 Billion CNY | 40.212% |
| Guangdong Hybribio Biotech Co.,Ltd. | 631.43 Million CNY | -11.293% |
| BGI Genomics Co., Ltd. | 1.93 Billion CNY | 63.762% |
| Amoy Diagnostics Co., Ltd. | 574.96 Million CNY | -22.223% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 479.96 Million CNY | -46.414% |